Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
—Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of...
Source: prnewswire.com